Close Menu

NEW YORK (GenomeWeb) – UgenTec announced today a partnership to develop artificially intelligent software to support interpretation of molecular test results for MDxHealth's ConfirmMDx and SelectMDx for prostate cancer tests.

MDxHealth's SelectMDx test is a liquid biopsy test that identifies patients with an increased risk for clinically significant prostate cancer. The firm's ConfirmMDx is a tissue biopsy test that allows patients to forgo unnecessary repeat biopsy procedures.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.